Assignee
GAMMADELTA THERAPEUTICS LTD
GB·5 granted patents·18 pending applications·0 citations·filing 2019–2025
Top patents by PatentIndex Score
23 records- 0170US12312408B2Multispecific anti-TCR delta variable 1 antibodiesGAMMADELTA THERAPEUTICS LTD·Filed 2023·Granted May 27, 2025·0 cites·14 claims
- 0270US2024376215A1Multispecific anti-tcr delta variable 1 antibodiesGAMMADELTA THERAPEUTICS LTD·Filed 2024·Application pending·0 cites
- 0367US2024082308A1Methods for treating myeloid malignanciesGAMMADELTA THERAPEUTICS LTD·Filed 2023·Application pending·0 cites
- 0466US12486313B2Gene armoringGAMMADELTA THERAPEUTICS LTD·Filed 2024·Granted Dec 2, 2025·0 cites·30 claims
- 0566US2025152630A1Methods for the production of tcr gamma delta + t cellsGAMMADELTA THERAPEUTICS LTD·Filed 2024·Application pending·0 cites
- 0663US2025352570A1Methods for treating myeloid malignanciesGAMMADELTA THERAPEUTICS LTD·Filed 2025·Application pending·0 cites
- 0761US2025025555A1Cells expressing an anti-mesothelin carGAMMADELTA THERAPEUTICS LTD·Filed 2024·Application pending·0 cites
- 0859US2024344024A1Engineering of gamma delta t cells and compositions thereofGAMMADELTA THERAPEUTICS LTD·Filed 2022·Application pending·0 cites
- 0958US12178832B2Methods for the production of TCR gamma delta + t cellsGAMMADELTA THERAPEUTICS LTD·Filed 2021·Granted Dec 31, 2024·0 cites·14 claims
- 1058US12173319B2Methods for the production of TCR gamma delta + T cellsGAMMADELTA THERAPEUTICS LTD·Filed 2021·Granted Dec 24, 2024·0 cites·17 claims
- 1157US2021290674A1Methods for treating myeloid malignanciesGAMMADELTA THERAPEUTICS LTD·Filed 2021·Application pending·0 cites
- 1257US2025340842A1Method for expanding gamma delta t cellsGAMMADELTA THERAPEUTICS LTD·Filed 2023·Application pending·0 cites
- 1350US2024197875A1Novel methodGAMMADELTA THERAPEUTICS LTD·Filed 2022·Application pending·0 cites
- 1450US2023159638A1Ex vivo gamma delta t cell populationsGAMMADELTA THERAPEUTICS LTD·Filed 2021·Application pending·0 cites
- 1550US2023090901A1Novel antibodiesGAMMADELTA THERAPEUTICS LTD·Filed 2021·Application pending·0 cites
- 1648US2023227777A1Methods for isolating gamma delta t cellsGAMMADELTA THERAPEUTICS LTD·Filed 2021·Application pending·0 cites
- 1747US2021015867A1Lymphocytes expressing heterologous targeting constructsGAMMADELTA THERAPEUTICS LTD·Filed 2019·Application pending·0 cites
- 1847US2023330143A1Immunotherapy compositionGAMMADELTA THERAPEUTICS LTD·Filed 2021·Application pending·0 cites
- 1943US2022403025A1Therapeutic uses of anti-tcr delta variable 1 antibodiesGAMMADELTA THERAPEUTICS LTD·Filed 2020·Application pending·0 cites
- 2042US12460180B2Methods for isolating and expanding cellsGAMMADELTA THERAPEUTICS LTD·Filed 2019·Granted Nov 4, 2025·0 cites·16 claims
- 2140US2023149459A1V delta1+ t cells for the treatment of myeloid malignanciesGAMMADELTA THERAPEUTICS LTD·Filed 2020·Application pending·0 cites
- 2239US2022290101A1Ex vivo gamma delta t cell populationsGAMMADELTA THERAPEUTICS LTD·Filed 2020·Application pending·0 cites
- 2338US2022010277A1Methods for isolating and expanding cellsGAMMADELTA THERAPEUTICS LTD·Filed 2019·Application pending·0 cites
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →